Who
Melvin K. Spigelman
Director
Company insider
Files Form 4 as: Director, AN2 Therapeutics; Director, Synergy Pharmaceuticals; Director, Medicines Co /de.
In numbers
- Trades disclosed
- 68
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $1.6M
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 25 May 2006
- Last trade
- 19 Mar 2026
- Last filed
- 23 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,941 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —16,941 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,362 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,941 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —16,941 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,362 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,362 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,742 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —23,742 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,362 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,742 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —23,742 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,400 at $0.00 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,400 at $0.00 | filing |
| 22 May 2025filed 23 May 2025 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,111 at $0.00 | filing |
| 19 Jun 2024filed 21 Jun 2024 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —64,503 at $0.00 | filing |
| 7 Jun 2023filed 9 Jun 2023 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,742 at $0.00 | filing |
| 12 May 2022filed 16 May 2022 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,362 at $0.00 | filing |
| 15 Aug 2018filed 16 Aug 2018 | Synergy Pharmaceuticalsoption or derivative | SEC FORM 4 Code M | —150,000 at $0.00 | filing |
| 15 Aug 2018filed 16 Aug 2018 | Synergy Pharmaceuticals | SEC FORM 4 Code M | $180K150,000 at $1.20 | filing |
News
No headline names them, or the companies they trade most, lately.